EchoCath begins selling ColorMark ultrasound imager
This article was originally published in Clinica
Executive Summary
EchoCath announced its first "meaningful revenue derived from the sale of its products". In the third quarter ending May 31, the company earned $142,000, from sales of its ColorMark system. This is used in the image enhancement of devices in ultrasound procedures and the licensing of other EchoCath technology.
You may also be interested in...
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements
Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.